electroCore

225 articles about electroCore

• electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance

  10/12/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited preliminary financial guidance for the third quarter of 2021.

• electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference

  9/30/2021

  electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30, 2021 at 12:40 PM eastern time. 

• electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

  9/29/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore SapphireTM in patients admitted to the hospital for treatment of COVID-19; is available on MedRxiv and has been submitted for peer review.

• electroCore to Participate at Upcoming Investor Conferences - Sep 23, 2021

  9/23/2021

  electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference.

• electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

  9/15/2021

   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods integrated with, or coupled to, smartphones that allow patients to self-treat medical conditions, such as migraine headache, by electrical non-invasive stimulation of nerves.

• electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

  9/14/2021

   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the treatment of Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults.

• electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference 

  8/31/2021

  electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference.

• electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.

  8/24/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One).

• Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

  8/10/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, “Transcutaneous Cervical Vagal Nerve Stimulation (tcVNS/nVNS) in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study of Effects on PTSD Symptoms and Interleukin-6 Response to Stress” in the Journal of Affective Disorders Reports.

• electroCore Announces Second Quarter 2021 Financial Results

  8/5/2021

  electroCore, Inc., a commercial-stage bioelectronic medicine company, announced second quarter 2021 financial results and provided an operational update.

• electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

  8/4/2021

  electroCore, Inc., a commercial-stage bioelectronic medicine company, announced the release of an article entitled “gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance” in the journal PharmacoEconomics highlighting the cost impact of gammaCore’s non-invasive vagus nerve stimulation therapy platform for patients with cluster headaches.

• electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

  7/27/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

• electroCore to Announce Second Quarter 2021 Financial Results on Thursday, August 5th

  7/22/2021

  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021.

• electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Neuroscience

  7/19/2021

  electroCore, Inc. today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.

• electroCore Provides Business Update and Select Second Quarter 2021 Financial Guidance

  7/13/2021

  electroCore, Inc., a commercial-stage bioelectronic medicine company, provided an operating and business update as well as select unaudited preliminary financial guidance for the second quarter of 2021.

• electroCore to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

  7/9/2021

  electroCore, Inc. today announced that Dan Goldberger, CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference: Ladenburg Thalmann 2021 Virtual Healthcare Conference Presentation Date: July 14, 2021 Presentation Time: 3:30 pm Webcast

• electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock

  6/30/2021

  electroCore, Inc. today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $1.00 per share.

• electroCore Announces Proposed Public Offering of Common Stock

  6/29/2021

  electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering

• electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive Performance Caused by Sleep Deprivation

  6/24/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10, 2021, entitled “Effects of Transcutaneous Vagal Nerve Stimulation (tVNS/nVNS) on Cognitive Performance under Sleep Deprivation Stress,” in the journal Communications Biology, a Nature publication.

• electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

  6/23/2021

  electroCore, Inc., a commercial-stage bioelectronic medicine company, announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator in Taiwan and China.